Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-03-03 @ 8:15 AM
Study NCT ID:
NCT03722420
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-28
First Post:
2018-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Sponsor:
Il-Yang Pharm. Co., Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Myeloid Leukemia, Chronic Phase | View |
Keywords: